Monday, November 9, 2026

FDA Formally Investigates Cancer Risk From Both Novartis SMA Gene Therapies After GLI1 Oncogene Activation Confirmed in Zolgensma Cases

Published: Nov 07 2026, Regulator extends scrutiny to Itvisma despite zero reported cases; three independent AAV programs now linked to developmental oncogene activation via shared CAG promoter element.

The U.S. Food and Drug Administration formally announced Thursday that it is investigating a serious risk of malignancy linked to both of Novartis's approved gene therapies for spinal muscular atrophy — Zolgensma and Itvisma — after molecular analysis of tumor tissue in Zolgensma patients confirmed a specific causal mechanism: the therapy's viral vector DNA integrating into the genome near a known cancer-driving gene called GLI1 and switching it on. 

 The FDA's action, published November 6 by its Center for Biologics Evaluation and Research (CBER), marks the first time a U.S. regulator has formally characterized a commercial AAV gene therapy as having caused insertional oncogenesis in humans — moving the risk from "theoretical," the language still on Zolgensma's product label, to confirmed and under active investigation.